UB Paderborn / Katalog / Suche / in CDI

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

The Lancet (British edition), 2015-05, Vol.385 (9980), p.1863-1872

2015

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

Journal of clinical oncology, 2002-10, Vol.20 (19), p.3947-3955

2002

Volltextzugriff (PDF)

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.143-150

2003

Volltextzugriff (PDF)

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

The New England journal of medicine, 2023-11, Vol.389 (20), p.1839-1850

2023

Volltextzugriff (PDF)

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Anticancer research, 2016-08, Vol.36 (8), p.4081

2016

Volltextzugriff (PDF)

Efficient Designs for Testing New Agents and Regimens

Chest, 1996-05, Vol.109 (5), p.83S-86S

Ardizzoni, Andrea

1996

Volltextzugriff (PDF)

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer : A phase II study in patients with refractory and sensitive disease

Journal of clinical oncology, 1997-05, Vol.15 (5), p.2090-2096

1997

Volltextzugriff (PDF)

Colony-Stimulating Factors for Febrile Neutropenia

The New England journal of medicine, 2013, Vol.369 (3), p.284-286

2013

Volltextzugriff (PDF)

A phase II study of gemcitabine in patients with malignant pleural mesothelioma

Cancer, 1999-06, Vol.85 (12), p.2577-2582

1999

Volltextzugriff (PDF)

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Journal of clinical oncology, 1996-03, Vol.14 (3), p.814-820

1996

Volltextzugriff (PDF)

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma

Cancer, 1997-05, Vol.79 (10), p.1897-1902

1997

Volltextzugriff (PDF)

Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the italian group on rare tumors (GITR) and the italian lung cancer task force (FONICAP)

Cancer, 2001-08, Vol.92 (3), p.650-656

2001

Volltextzugriff (PDF)

Management of malignant pleural effusions

Drugs (New York, N.Y.), 1998, Vol.55 (1), p.47-58

1998

Volltextzugriff (PDF)

Teniposide for brain metastases of small-cell lung cancer : a phase II study

Journal of clinical oncology, 1995-03, Vol.13 (3), p.660-665

1995

Volltextzugriff (PDF)

Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma

Cancer, 2001-08, Vol.92 (3), p.650-656

2001

Volltextzugriff (PDF)

Anti‐insulin‐like growth factor‐I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines

British journal of pharmacology, 1997-02, Vol.120 (3), p.537-543

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Efficient Designs for Testing New Agents and Regimens

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer : A phase II study in patients with refractory and sensitive disease

Colony-Stimulating Factors for Febrile Neutropenia

A phase II study of gemcitabine in patients with malignant pleural mesothelioma

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma

Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the italian group on rare tumors (GITR) and the italian lung cancer task force (FONICAP)

Management of malignant pleural effusions

Teniposide for brain metastases of small-cell lung cancer : a phase II study

Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma

Anti‐insulin‐like growth factor‐I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines

Etoposide versus etoposide plus high‐dose cisplatin in the management of advanced non‐small cell lung cancer: Results of a prospective randomized fonicap trial

Aktive Filter

Suchergebnisse filtern